Lisata Therapeutics CEO Encouraged by Progress on Pancreatic Cancer Trial
Lisata Therapeutics CEO discusses completion of patient enrollment for pancreatic cancer trial in Phase 1B/2A CENDIFOX trial
The completion of patient enrollment for the pancreatic cancer cohorts in Lisata Therapeutics' Phase 1B/2A CENDIFOX trial marks a significant milestone in the evaluation of certepetide's safety and efficacy. This progress brings hope to patients with pancreatic, colon, and appendiceal cancers, and the collection of pre- and post-treatment biopsies could lead to valuable insights for future treatments.